Literature DB >> 27660932

Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months After Total Knee Arthroplasty.

Arielle W Fein1, Caroline A Figgie, Taylor R Dodds, Joshua Wright-Chisem, Michael L Parks, Lisa A Mandl, Edwin P Su, Jane E Salmon, David J Mayman, Yuo-Yu Lee, Mark P Figgie, Susan M Goodman.   

Abstract

BACKGROUND: Increasing numbers of patients with systemic lupus erythematosus (SLE) are undergoing total knee arthroplasty (TKA). Whether postsurgical adverse events (AEs) are higher in patients with SLE than patients with osteoarthritis (OA) is unknown.
OBJECTIVES: This study aims to compare AEs within 6 months of TKA.
METHODS: Patients in a single institution's arthroplasty and SLE registries who underwent TKA from 2007 to 2014 were eligible. SLE cases were matched 1:2 to OA on age, sex, year of TKA, and procedure type. AEs were collected through chart review and registry responses. Baseline characteristics were compared and regression analysis performed to determine predictors of AEs.
RESULTS: Fifty-two SLE TKA were matched to 104 OA TKA. There was no difference in follow-up between groups. SLE patients had more comorbidities (≥1 Charlson-Deyo comorbidity: SLE 38.4% vs. OA 17.3%; P-value < 0.001) and steroid use (preoperative [SLE 28.8% vs. OA 1.9%, P-value < 0.001] and perioperative "stress-dose" [30.8% vs. 2.9%, P-value = 0.01]). SLE patients did not experience more major (SLE 25.0% vs. OA 19.2%; P-value = 0.41), minor (15.4% vs. 10.6%; P-value = 0.39), or total (38.5% vs. 27.9%; P-value = 0.18) AEs. AEs were not increased among patients on stress-dose steroids. In a multiple logistic regression analysis controlling for comorbidities and diagnosis, neither SLE (OR 1.61, 95% CI 0.74-3.50) nor >1 comorbidity (OR 1.05, 95% CI 0.46-2.39) was an independent risk factor for AEs.
CONCLUSION: SLE is not an independent risk factor for increased AEs 6 months after TKA. Stress-dose steroid use does not heighten AE risk. These findings should inform recommendations for SLE patients considering TKA.

Entities:  

Mesh:

Year:  2016        PMID: 27660932     DOI: 10.1097/RHU.0000000000000435

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  6 in total

Review 1.  Prevention of Infection in the Perioperative Setting in Patients with Rheumatic Disease Treated with Immunosuppression.

Authors:  Joshua F Baker; Michael D George
Journal:  Curr Rheumatol Rep       Date:  2019-03-08       Impact factor: 4.592

2.  Does systemic lupus erythematosus impact the peri-operative complication rates following primary total knee arthroplasty? A national inpatient sample-based large-scale study.

Authors:  Vibhu Krishnan Viswanathan; Vishaal Sakthivelnathan; Tejas Senthil; Anil Menedal; Prabhudev Prasad Purudappa; Varatharaj Mounasamy; Senthil Sambandam
Journal:  Arch Orthop Trauma Surg       Date:  2022-08-17       Impact factor: 2.928

3.  Systemic Lupus Erythematosus is a Risk Factor for Complications in Total Joint Arthroplasty.

Authors:  J Joseph Gholson; Brandon G Wilkinson; Timothy S Brown; Yubo Gao; S Blake Dowdle; John J Callaghan
Journal:  Iowa Orthop J       Date:  2018

4.  A systematic review and meta-analysis comparing complications following total hip arthroplasty for systemic lupus erythematosus versus for non-systemic lupus erythematosus.

Authors:  Yiwei Huang; Danni Guan; Yijin Li; Jiahao Li; Yirong Zeng
Journal:  J Orthop Surg Res       Date:  2022-04-12       Impact factor: 2.359

Review 5.  Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview.

Authors:  Roberta Gualtierotti; Marco Parisi; Francesca Ingegnoli
Journal:  Adv Ther       Date:  2018-03-20       Impact factor: 3.845

6.  The impact of systemic lupus erythematosus on the risk of infection after total hip arthroplasty: a nationwide population-based matched cohort study.

Authors:  Chien-Hao Chen; Tien-Hsing Chen; Yu-Sheng Lin; Dave W Chen; Chi-Chin Sun; Liang-Tseng Kuo; Shih-Chieh Shao
Journal:  Arthritis Res Ther       Date:  2020-09-14       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.